

Buy

Laurus Labs Ltd.

04th July, 2024

Buy

Target : 505

Stop Loss : 430

CMP : 450

Range : 450-455

Period : 1 Month



Laurus Labs Ltd. (LAURUSLABS)

- ▲ We are seeing collective strength in pharma stocks and Lauruslabs is showing renewed buying interest within the space.
- ▲ On the weekly chart, the stock is trading in a rising channel where prices found support around the lower end of the channel and edged higher.
- ▲ Also, it has ended its long term corrective phase by surpassing the levels of 445-450. The prices have retested its long-term moving averages and the momentum indicator has also given a bullish crossover.
- ▲ All the technical parameters coincides with the fact that the stock has strong potential on the upside.



Open Calls

Running Recommendations

Scrip Symbol	Rec. Date	Rec. Price	Closing Price (30th Nov., 2023)	S/L	Target
EPL	01-Jul-24	200	227.55	192	235*
*Target Revised					

Performance of Closed Recommendations

Scrip Symbol	Rec. Date	Rec. Price	Closing On	Return %	Remarks
RBLBANK	20-Jun-24	266	24-Jun-24	-3.41	Exit at 255
PRAJIND	07-Jun-24	560	12-Jun-24	12.5	Booked Profit at 630
LAURUSLABS	21-May-24	443	30-May-24	-3.50	Exit at 428
GUJALKALI	04-Jan-24	808	16-Jan-24	-5.32	Exit at 765
KNRCON	21-Nov-23	284	05-Dec-23	-5.63	Exit at 268
GRAPHITE	1-Dec-23	510	20-Dec-23	8.24	Booked Profit at 552
CIEINDIA	15-Nov-23	488	28-Nov-23	-4.71	Exit at 465
KRBL	07-Sep-23	438	13-Sep-23	-5.02	Exit at 416
CESC	24-Aug-23	83	12-Sep-23	9.64	Booked Profit at 91
JAMNAAUTO	31-Aug-23	117	05-Sep-23	5.12	Booked Profit at 123
RITES	09-Aug-23	469	10-Aug-23	0.85	Booked Profit at 473
FSL	17-Jul-23	140	7-Aug-23	4.29	Booked Profit at 146
KRBL	20-Jul-23	376	02-Aug-23	2.13	Booked Profit at 384
GHCL	30-Jun-23	510	10-Jul-23	3.92	Booked Profit at 530
KPRMILL	21-Jun-23	665	11-Jul-23	-6.00	Exit at 625
HFCL	08-Jun-23	69	23-Jun-23	-4.34	Exit at 66
QUESS	31-May-23	407	06-Jun-23	3.19	Booked Profit at 420
ELGIEQUIP	19-Apr-23	490	28-Apr-23	-5.00	Exit at 465
MAZDOCK	01-Mar-23	738	14-Mar-23	-5.40	Exit at 698
REDINGTON	02-Jan-23	184	04-Jan-23	0.54	Booked Profit at 185
JUBLINGREA	10-Nov-22	574	26-Dec-22	-10.28	Exit at 515
VTL	05-Dec-22	350	07-Dec-22	-2.00	Exit at 338
IRB	10-Nov-22	250	01-Dec-22	12.00	Booked Profit at 280
SPARC	28-Oct-22	244	02-Nov-22	3.69	Booked Profit at 253
ELGIEQUIP	17-Oct-22	438	21-Oct-22	13.93	Booked Profit at 499
WELCORP	06-Oct-22	270	11-Oct-22	-5.56	Exit at 255
GAEL	21-Sep-22	296	28-Sep-22	-7.09	Exit at 275
VIPIND	14-Sep-22	640	20-Sep-22	5.47	Target Achieved at 675
CHALET	15-Sep-22	350	16-Sep-22	-4.57	Exit at 336.65



Research Team

Name	Email ID
Ajit Mishra	ajit.mishra@religare.com
Gaurav Arora	gaurav.arora3@religare.com
Abhijeet Banerjee	abhijeet.banerjee@religare.com
Gaurav Sharma	gauravsharma2@religare.com
Rohan Shah	rohan.shah@religare.com
Ashwani Harit	ashwani.harit@religare.com
Divya Parmar	divya.parmar@religare.com



Disclaimer

Before you use this research report, please ensure to go through the disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 and Research Disclaimer at the following link : <https://www.religareonline.com/disclaimer>

Specific analyst(s) specific disclosure(s) inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 is/are as under:

Statements on ownership and material conflicts of interest, compensation– Research Analyst (RA)

[Please note that only in case of multiple RAs, if in the event answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) below, are given separately]

S. No.	Statement	Answer	
		Yes	No
		Tick appropriate	
	I/we or any of my/our relative has any financial interest in the subject company? [If answer is yes, nature of Interest is given below this table]		No
	I/we or any of my/our relatives, have actual/beneficial ownership of one per cent. or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance?		No
	I / we or any of my/our relative, has any other material conflict of interest at the time of publication of the research report or at the time of public appearance?		No
	I/we have received any compensation from the subject company in the past twelve months?		No
	I/we have managed or co-managed public offering of securities for the subject company in the past twelve months?		No
	I/we have received any compensation for brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation for products or services other than brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation or other benefits from the subject company or third party in connection with the research report?		No
	I/we have served as an officer, director or employee of the subject company?		No
	I/we have been engaged in market making activity for the subject company?		No

Nature of Interest (if answer to F (a) above is Yes :

Name(s) with Signature(s) of RA(s).

[Please note that only in case of multiple RAs and if the answers differ inter-se between the RAs, then RA specific answer with respect to questions under F (a) to F(j) above, are given below]

SS.No.	Name(s) of RA.	Signatures of RA	Serial Question of question which the signing RA needs to make a separate declaration / answer	Yes	No.

Copyright in this document vests exclusively with RBL. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from RBL. We do not guarantee the integrity of any emails or attached files and are not responsible for any changes made to them by any other person.

